| 1147335-30-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• CAS: 1147335-30-5
• 化学式: C₉H₆ClN₃O₃
• 分子量: 239.618
• InChiKey: SLEDNIKNORKEQB-UHFFFAOYSA-N

物化性质

• 沸点：
  440.3±55.0 °C(predicted)
• 密度：
  1.58±0.1 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.44
• 重原子数：
  16.0
• 可旋转键数：
  2.0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  85.56
• 氢给体数：
  1.0
• 氢受体数：
  5.0

反应信息

• 作为反应物：
  描述：

  在 氯化亚砜 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 4-(3-chlorophenyl)-3-cyano-1,2,5-oxadiazole 2-oxide
  参考文献：
  名称：

  Synthesis of oxadiazole-2-oxide analogues as potential antischistosomal agents

  摘要：

  The synthesis of several 1,2,5-oxadiazole-2-oxide (Furoxan) analogues is described herein. These compounds were prepared in an effort to probe the SAR around the phenyl substituent and oxadiazole core for our studies toward thioredoxin-glutathione reductase (TGR) inhibition and antischistosomal activity. Published by Elsevier Ltd.

  DOI：

  10.1016/j.tetlet.2009.01.120
• 作为产物：
  描述：

  4-(3-chlorophenyl)-3-formyl-1,2,5-oxadiazole 2-oxide 在 盐酸羟胺 、 sodium acetate 作用下， 以 乙醇 为溶剂， 生成
  参考文献：
  名称：

  Synthesis of oxadiazole-2-oxide analogues as potential antischistosomal agents

  摘要：

  The synthesis of several 1,2,5-oxadiazole-2-oxide (Furoxan) analogues is described herein. These compounds were prepared in an effort to probe the SAR around the phenyl substituent and oxadiazole core for our studies toward thioredoxin-glutathione reductase (TGR) inhibition and antischistosomal activity. Published by Elsevier Ltd.

  DOI：

  10.1016/j.tetlet.2009.01.120

文献信息

• Structure Mechanism Insights and the Role of Nitric Oxide Donation Guide the Development of Oxadiazole-2-Oxides as Therapeutic Agents against Schistosomiasis
  作者：Ganesha Rai、Ahmed A. Sayed、Wendy A. Lea、Hans F. Luecke、Harinath Chakrapani、Stefanie Prast-Nielsen、Ajit Jadhav、William Leister、Min Shen、James Inglese、Christopher P. Austin、Larry Keefer、Elias S. J. Arnér、Anton Simeonov、David J. Maloney、David L. Williams、Craig J. Thomas

  DOI：10.1021/jm901021k

  日期：2009.10.22

  Schistosomiasis is a chronic parasitic disease affecting hundreds of millions of individuals worldwide. Current treatment depends on a single agent, praziquantel, raising concerns of emergence of resistant parasites. Here, we continue our explorations of an oxadiazole-2-oxide class of compounds we recently identified as inhibitors of thioredoxin glutathione reductase (TGR), a selenocysteine-containing flavoenzyme required by the parasite to maintain proper cellular redox balance. Through systematic evaluation of the core molecular structure of this chemotype, we define the essential pharmacophore, establish a link between the nitric oxide donation and TGR inhibition, determine the selectivity for this chemotype versus related reductase enzymes, and present evidence that these agents can be modified to possess appropriate drug metabolism and pharmacokinetic properties. The mechanistic link between exogenous NO donation and parasite injury is expanded and better defined. The results of these studies verify the utility of oxadiazole-2-oxides as novel inhibitors of TGR and as efficacious antischistosomal agents.